Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$6.86

0.13 (1.93%)

, ICPT

Intercept

$90.75

-7.37 (-7.51%)

07:14
09/14/17
09/14
07:14
09/14/17
07:14

Intercept Ocaliva dynamics highlight PBC opportunity, says Oppenheimer

Oppenheimer analyst Jay Olson says the Dear Doctor letter for Intercept's (ICPT) Ocaliva raises awareness of unmet medical need for patients with primary biliary cholangitis, or PBC. Since patients with Child-Pugh B/C cirrhosis were not studied in Ocaliva trials, the analyst believes the FDA's collaboration with Intercept to leverage PK modeling for dosing guidance which is included in the label and emphasized in the Dear Doctor letter highlights the importance of providing novel treatments to PBC patients. Olson expects these events to have a positive impact on the treatment of all PBC patients, and says CymaBay (CBAY) may benefit from these dynamics. He reiterates an Outperform rating and $15 price target on CymaBay's shares.

CBAY

CymaBay

$6.86

0.13 (1.93%)

ICPT

Intercept

$90.75

-7.37 (-7.51%)

  • 25

    Sep

CBAY CymaBay
$6.86

0.13 (1.93%)

07/25/17
PIPR
07/25/17
NO CHANGE
Target $12
PIPR
Overweight
CymaBay price target raised to $12 from $6.50 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for CymaBay Therapeutics to $12 to reflect increasing value for seladelpar. Importantly, no liver transaminase signals nor drug-induced pruritus were observed in the "positive" Phase II data in 24 primary biliary cholangitis patients receiving seladelpar, the analyst contends. He reiterates an Overweight rating on CymaBay shares.
08/11/17
IFSG
08/11/17
DOWNGRADE
Target $13
IFSG
Outperform
CymaBay downgraded to Outperform from Strong Buy at IFS Securities
IFS Securities analyst David Bouchey downgraded CymaBay to Outperform from Strong Buy, saying he sees now as a good time to step back with additional news flow not expected to pick until 2018. He lowered his price target on CymaBay to $13 from $18.
08/18/17
RHCO
08/18/17
INITIATION
RHCO
Buy
CymaBay initiated with a Buy at SunTrust
SunTrust analyst Edward Nash started coverage of CymaBay with a $15 price target and a Buy rating. He is upbeat on the outlook for the company's seladelpar, a treatment for a rare liver disease called primary biliary cholangitis. According to the analyst ,the drug has "well defined approvable endpoints and a primed commercial opportunity,"
08/23/17
LEER
08/23/17
INITIATION
Target $12
LEER
Outperform
CymaBay initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started CymaBay with an Outperform rating and $12 price target, noting that the company is currently developing seladelpar for the lead indication of primary biliary cholangitis, an autoimmune disease that causes progressive destruction of the bile ducts in the liver.
ICPT Intercept
$90.75

-7.37 (-7.51%)

09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.
09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.
09/13/17
BMOC
09/13/17
NO CHANGE
BMOC
Intercept should be bought on weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.
09/13/17
JMPS
09/13/17
NO CHANGE
Target $150
JMPS
Outperform
Intercept letter doesn't change fundamental view of Ocaliva, says JMP Securities
JMP Securities analyst Liisa Bayko said the warning letter sent by Intercept to health care providers regarding post-marketing reports of liver issues and death in certain PBC patients highlights risks that were already known and doesn't change her fundamental view on Ocaliva. The analyst, who sees little read through to the ongoing Phase 3 REGENERATE trial in NASH patients and views yesterday's drop in Intercept shares as an overreaction, keeps an Outperform rating and $150 price target on the stock.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

12:16
11/20/17
11/20
12:16
11/20/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSL

Fossil

$7.95

0.33 (4.33%)

12:15
11/20/17
11/20
12:15
11/20/17
12:15
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KORS

Michael Kors

$56.42

0.13 (0.23%)

12:13
11/20/17
11/20
12:13
11/20/17
12:13
Conference/Events
Michael Kors management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 11

    Dec

SECO

Seeco Holding

$8.26

0.04 (0.49%)

12:10
11/20/17
11/20
12:10
11/20/17
12:10
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 23

    Nov

MRO

Marathon Oil

$14.63

-0.425 (-2.82%)

12:05
11/20/17
11/20
12:05
11/20/17
12:05
Options
Marathon Oil call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CG

Carlyle Group

$21.10

0.05 (0.24%)

12:00
11/20/17
11/20
12:00
11/20/17
12:00
Hot Stocks
Carlyle Group to acquire BenefitMall, terms not disclosed »

Carlyle Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.04

-0.57 (-0.61%)

12:00
11/20/17
11/20
12:00
11/20/17
12:00
Recommendations
AbbVie analyst commentary  »

AbbVie price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$17.68

0.025 (0.14%)

11:58
11/20/17
11/20
11:58
11/20/17
11:58
Hot Stocks
New York Times suspends Glenn Thrush following allegations of sexual misconduct »

The New York Times said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
11/20/17
11/20
11:55
11/20/17
11:55
General news
Treasury's $78 B 3- and 6-month bill sale was a little better than average »

Treasury's $78 B 3-…

CBS

CBS

$56.02

-0.72 (-1.27%)

, DISH

Dish

$50.66

0.16 (0.32%)

11:53
11/20/17
11/20
11:53
11/20/17
11:53
Periodicals
CBS: Dish could black out certain programs if pact not reached, Reuters says »

CBS (CBS) warned that…

CBS

CBS

$56.02

-0.72 (-1.27%)

DISH

Dish

$50.66

0.16 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAKE

Cheesecake Factory

$45.44

0.52 (1.16%)

11:50
11/20/17
11/20
11:50
11/20/17
11:50
Options
Cheesecake option volume is 2X daily average as buyers gobble up call options »

Cheesecake option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
11/20/17
11/20
11:50
11/20/17
11:50
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

SPY

SPDR S&P 500 ETF Trust

$258.20

0.34 (0.13%)

, SPX

S&P 500

11:48
11/20/17
11/20
11:48
11/20/17
11:48
General news
President Trump says U.S. to designate North Korea a state sponsor of terror »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$258.20

0.34 (0.13%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAH

Cardinal Health

$55.62

-1.89 (-3.29%)

, AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

11:44
11/20/17
11/20
11:44
11/20/17
11:44
Hot Stocks
Cardinal Health slides as Morgan Stanley says sell on Amazon risk »

Shares of Cardinal Health…

CAH

Cardinal Health

$55.62

-1.89 (-3.29%)

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

PDCO

Patterson Companies

$36.04

-0.03 (-0.08%)

HSIC

Henry Schein

$69.12

-0.39 (-0.56%)

CVS

CVS Health

$70.02

-0.66 (-0.93%)

WBA

Walgreens Boots Alliance

$71.25

-0.05 (-0.07%)

MCK

McKesson

$138.41

-3.72 (-2.62%)

ABC

AmerisourceBergen

$77.22

-1.625 (-2.06%)

TMO

Thermo Fisher

$190.62

0.45 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 12

    Dec

  • 18

    Mar

TRP

TransCanada

$49.73

0.75 (1.53%)

11:42
11/20/17
11/20
11:42
11/20/17
11:42
Hot Stocks
Nebraska approves TransCanada's Keystone XL pipeline »

The Nebraska Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$17.92

-0.29 (-1.59%)

11:40
11/20/17
11/20
11:40
11/20/17
11:40
Options
GE draws a $2.35M call buyer as shares revisit recent lows »

GE draws a $2.35M call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:40
11/20/17
11/20
11:40
11/20/17
11:40
General news
Euro$ interest rate futures trickled lower »

Euro$ interest rate…

CAVM

Cavium

$75.83

-0.47 (-0.62%)

11:33
11/20/17
11/20
11:33
11/20/17
11:33
Downgrade
Cavium rating change  »

Cavium downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

FCAU

Fiat Chrysler

$17.62

0.255 (1.47%)

11:30
11/20/17
11/20
11:30
11/20/17
11:30
Options
Higher option volume in Fiat driven by longer-term call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$46.16

-0.02 (-0.04%)

11:22
11/20/17
11/20
11:22
11/20/17
11:22
Technical Analysis
Technical View: Micron trades to new 52-week highs »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 19

    Dec

XOP

SPDR Oil Exploration and Production Fund

$34.45

-0.55 (-1.57%)

11:20
11/20/17
11/20
11:20
11/20/17
11:20
Options
SPDR Oil Exploration and Production puts active »

SPDR Oil Exploration and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
11/20/17
11/20
11:17
11/20/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
11/20/17
11/20
11:16
11/20/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$138.89

-3.24 (-2.28%)

11:15
11/20/17
11/20
11:15
11/20/17
11:15
Options
McKesson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

11:15
11/20/17
11/20
11:15
11/20/17
11:15
General news
Treasury announced a $45 B 4-week bill sale for Tuesday »

Treasury announced a $45…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.